RealSeq Biosciences, Inc., a Santa Cruz, CA-based biotechnology company focused on RNA-based diagnostics, extended its Seed funding.
The round was led by new investors Charleston Angel Partners, Santa Clara Ventures, and Santa Cruz Ventures, with participation from earlier investors.
The company intends to use the funds to accelerate development of its Ribomarker platform for biomarker discovery and of its liquid biopsy program.
Led by CEO Dr. Sergio Barberan-Soler, RealSeq Biosciences is a biotechnology company dedicated to developing RNA technologies for biomarker discovery and liquid biopsy programs. With the Ribomarker platform, it has discovered a way to profile complete transcriptomics from liquid biopsies by analyzing RNA fragments. Ribomarkers can provide insights into disease progression and treatment response with potential to greatly improve patient outcomes and reduce healthcare costs.
Commenting on the news, Sergio Barberan-Soler said: “This additional funding allows us to accelerate our research and development and bring our innovative Ribomarker platform to the market faster. We are confident that our transcriptomic analysis technologies will have a significant impact on the field of biomarker discovery and liquid biopsy, and ultimately improve patient outcomes.“
FinSMEs
13/03/2024